• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

    4/12/24 8:04:19 AM ET
    $APLD
    $ESPR
    $JD
    $KEP
    Finance: Consumer Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APLD alert in real time by email

    U.S. stock futures were mixed this morning, with the Dow futures gaining over 50 points on Friday.

    Shares of Applied Digital Corporation (NASDAQ:APLD) fell sharply in today’s pre-market trading after the company reported worse-than-expected third-quarter financial results.

    Applied Digital posted a quarterly loss of 24 cents per share, versus a year-ago loss of 10 cents per share. The company’s quarterly sales came in at $43.35 million versus expectations of $51.92 million, according to data from Benzinga Pro.

    Applied Digital shares dipped 9.1% to $2.79 in pre-market trading.

    Here are some big stocks recording losses in today’s pre-market trading session.

    • Tevogen Bio Holdings Inc. (NASDAQ:TVGN) shares declined 8.5% to $2.26 in pre-market trading.
    • Nurix Therapeutics, Inc. (NASDAQ:NRIX) shares declined 6.3% to $16.12 pre-market trading after the company priced its upsized $175m public offering of 10,166,667 common shares at $15 per share.
    • XPeng Inc. (NYSE:XPEV) shares fell 4.6% to $7.89 in pre-market trading.
    • Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shares fell 3.7% to $3.10 in pre-market trading.
    • Korea Electric Power Corporation (NYSE:KEP) shares declined 3.2% to $7.54 in pre-market trading after falling over 3% on Thursday.
    • Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares fell 3.1% to $2.24 in pre-market trading after dipping 8% on Thursday.
    • JD.com, Inc. (NASDAQ:JD) shares fell 3% to $26.20 in pre-market trading.

     

    Now Read This: Citigroup, JPMorgan And 3 Stocks To Watch Heading Into Friday

    Don’t forget to check out our premarket coverage here

    Get the next $APLD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APLD
    $ESPR
    $JD
    $KEP

    CompanyDatePrice TargetRatingAnalyst
    Tevogen Bio Holdings Inc.
    $TVGN
    3/4/2026Buy → Hold
    D. Boral Capital
    Nurix Therapeutics Inc.
    $NRIX
    1/8/2026$36.00Equal-Weight → Overweight
    Morgan Stanley
    Applied Digital Corporation
    $APLD
    1/7/2026$99.00Buy
    Arete
    JD.com Inc.
    $JD
    12/9/2025$32.00Buy → Neutral
    Arete
    Esperion Therapeutics Inc.
    $ESPR
    11/25/2025$9.00Overweight
    Piper Sandler
    Nurix Therapeutics Inc.
    $NRIX
    11/24/2025$30.00Buy
    Truist
    XPeng Inc.
    $XPEV
    11/18/2025$29.00Neutral → Buy
    Daiwa Securities
    JD.com Inc.
    $JD
    11/10/2025$28.00Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings

    $APLD
    $ESPR
    $JD
    $KEP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Xu Ran

    3 - JD.com, Inc. (0001549802) (Issuer)

    3/18/26 9:08:23 PM ET
    $JD
    Other Specialty Stores
    Consumer Discretionary

    SEC Form 3 filed by new insider Ding Kun

    3 - JD.com, Inc. (0001549802) (Issuer)

    3/18/26 6:31:50 PM ET
    $JD
    Other Specialty Stores
    Consumer Discretionary

    SEC Form 3 filed by new insider Shan Su

    3 - JD.com, Inc. (0001549802) (Issuer)

    3/18/26 6:28:42 PM ET
    $JD
    Other Specialty Stores
    Consumer Discretionary

    $APLD
    $ESPR
    $JD
    $KEP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:30 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:37 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLETOL issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy

    3/25/24 4:41:29 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLD
    $ESPR
    $JD
    $KEP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tevogen Bio downgraded by D. Boral Capital

    D. Boral Capital downgraded Tevogen Bio from Buy to Hold

    3/4/26 9:36:27 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nurix Therapeutics upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Nurix Therapeutics from Equal-Weight to Overweight and set a new price target of $36.00

    1/8/26 8:12:12 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arete initiated coverage on Applied Digital with a new price target

    Arete initiated coverage of Applied Digital with a rating of Buy and set a new price target of $99.00

    1/7/26 9:08:58 AM ET
    $APLD
    Finance: Consumer Services
    Finance

    $APLD
    $ESPR
    $JD
    $KEP
    SEC Filings

    View All

    Amendment: Applied Digital Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - Applied Digital Corp. (0001144879) (Filer)

    3/13/26 5:29:08 PM ET
    $APLD
    Finance: Consumer Services
    Finance

    SEC Form 6-K filed by Korea Electric Power Corporation

    6-K - KOREA ELECTRIC POWER CORP (0000887225) (Filer)

    3/13/26 3:09:36 PM ET
    $KEP
    Electric Utilities: Central
    Utilities

    SEC Form 10-K filed by Esperion Therapeutics Inc.

    10-K - Esperion Therapeutics, Inc. (0001434868) (Filer)

    3/10/26 4:55:11 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLD
    $ESPR
    $JD
    $KEP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Manning Paul B bought $2,062,500 worth of shares (750,000 units at $2.75) (SEC Form 4)

    4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

    6/3/25 9:38:27 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Manning Paul B bought $2,999,999 worth of shares (1,333,333 units at $2.25) (SEC Form 4)

    4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

    7/1/24 8:00:07 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Desai Kirti bought $2,460 worth of shares (3,000 units at $0.82), increasing direct ownership by 0.03% to 9,699,186 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    6/13/24 4:30:24 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APLD
    $ESPR
    $JD
    $KEP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

    WARREN, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, will speak at the Microsoft Fabric Community Conference (FabCon 2026), taking place March 16–20, 2026, in Atlanta, Georgia. Mr. Mehta will participate in two sessions focused on the evolving intersection of data engineering and artificial intelligence: From Risk to Reward: Modernizing the Data Estate to Power Enterprise AIWednesday, March 18, 4:30PM – 5:05PM alongside Dipti Borkar, VP & GM OneLake & ISVs at Microsoft and Tripti Sethi, Data & AI Lead at Avanade.Agentic Data Engineering on Micr

    3/18/26 12:22:11 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session

    Reviews Bempedoic Acid as Therapeutic Option for Diverse Patient Populations in Need of Alternatives to Statins in Cardiovascular Risk Management ANN ARBOR, Mich., March 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two abstracts have been accepted for presentation in moderated poster sessions at the upcoming American College of Cardiology's 2026 Annual Scientific Session (ACC.26) taking place March 28-30, 2026 in New Orleans, LA. "ACC.26 provides an important platform to share new insights from the CLEAR Outcomes trial among an audience of the world's leading cardiologists," said Sheldon Koenig, Chief Executive Officer of Esperion. "These analyses deepen our u

    3/17/26 8:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

    – Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolemia – – Bempedoic Acid Receives Equal Positioning with PCSK9 mAb and Ezetimibe After Statins for High-Risk Primary Prevention and Clinical ASCVD Not at Very High-Risk Patients – – Guideline Recognition of Early Combination Lipid-Lowering Therapy and Reintroduction of LDL-C Goals Affirms ‘Lower for Longer is Better' Approach to Cardiovascular Risk Reduction – ANN ARBOR, Mich., March 16, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) welcomed the inclusion of bempedoic acid for LDL-C lowering

    3/16/26 6:30:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLD
    $ESPR
    $JD
    $KEP
    Leadership Updates

    Live Leadership Updates

    View All

    Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

    WARREN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today issued a statement from Founder and CEO Dr. Ryan Saadi regarding the company's progress in developing TVGN 489 for Long COVID, timed with International Long COVID Awareness Month. Following the appointment of a new leadership team on March 9, 2026, Tevogen is accelerating its "Biotech" and "Digital Health" verticals to move TVGN 489 into its next clinical phase. The company is currently evaluating the acquisition of Sciometrix and its Clinicus platform to provide real-world monitoring for Long COVID patients. Tevogen continues to prioritize the development of TVGN 489,

    3/11/26 3:15:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Names Leadership Team to Execute Diversified Growth Strategy

    WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced the appointment of interim leaders across its core business verticals to execute the first phase of its diversified growth strategy. In this first phase, Tevogen is evaluating strategic opportunities that, if completed, are expected to operate as subsidiaries of the Company and could collectively generate annual revenues exceeding $50 million. The Company expects these transactions to close by the second quarter of 2026, subject to customary due diligence and definitive agreements. Leadership Designations: Digital Health: Arpita Patel and Wojtek StobinskiGene

    3/9/26 7:45:00 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Applied Digital Appoints Co-Founder Jason Zhang as President

    DALLAS, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ:APLD), a designer, builder, and operator of high-performance, sustainably engineered data centers and colocation services for artificial intelligence, cloud, networking, and blockchain workloads, today announced the appointment of its co-founder and current Chief Strategy Officer, Jason Zhang, as the company's President. As one of the founders of Applied Digital, Mr. Zhang has been instrumental in fueling the company's innovation, working closely with co-founder Wes Cummins. The appointment reflects the role Mr. Zhang has long played in shaping the company's strategy and long-term growth trajectory. As President, Mr. Zhang

    1/15/26 8:00:00 AM ET
    $APLD
    Finance: Consumer Services
    Finance

    $APLD
    $ESPR
    $JD
    $KEP
    Financials

    Live finance-specific insights

    View All

    Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

    Lead investor confirmed his intention to maintain his current shareholdings.Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next 12 months or until the company becomes cash-flow positive.Approximately only one-fifth of total shares outstanding are in the tradable float when accounting for Tevogen's lead investor, directors and named executive officers.Company prioritizing long-term stock-based incentive program aligned with company milestones.Board of Directors continues to evaluate the potential declaration of a one-time special cash dividend to shareholders.Company continues to evaluate acquisitions that could generate

    3/13/26 2:45:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19

    DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2025, and host a corporate update conference call and webcast on Thursday, March 19, 2026, at 8:30 AM Eastern Time. Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha's website at ir.tayshagtx.com. An archived replay of the webcast will be available on

    3/12/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    – FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., March 10, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted co

    3/10/26 6:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLD
    $ESPR
    $JD
    $KEP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Applied Digital Corporation

    SC 13D/A - Applied Digital Corp. (0001144879) (Subject)

    11/29/24 4:20:07 PM ET
    $APLD
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 9:00:57 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Taysha Gene Therapies Inc.

    SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

    11/14/24 5:51:11 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care